Author:
Tallantyre E. C.,Whittam D. H.,Jolles S.,Paling D.,Constantinesecu C.,Robertson N. P.,Jacob A.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference27 articles.
1. Collongues N, de Seze J (2016) An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 9:180–188.
https://doi.org/10.1177/1756285616632653
2. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688.
https://doi.org/10.1056/NEJMoa0706383
3. Naismith RT, Piccio L, Lyons JA et al (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74:1860–1867.
https://doi.org/10.1212/WNL.0b013e3181e24373
4. Ali R, Nicholas RSJ, Muraro PA (2013) Drugs in development for relapsing multiple sclerosis. Drugs 73:625–650.
https://doi.org/10.1007/s40265-013-0030-6
5. Hauser SL, Comi GC, Hartung H-P et al (2016) Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: results of the IFN-beta-1a-controlled, double-blind, Phase III OPERA I and II studies. Mult Scler J 22:17–18
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献